glioblastoma

[Science Translational Medicine] developed synthetic notch (synNotch)–CAR T cells targeting solid tumor antigens and used them to treat mouse models of mesothelioma, ovarian cancer, and glioblastoma.

[PLoS One] To improve treatment of glioblastoma, including those resistant to temozolomide , we explored the potential of targeting dopamine receptor signaling.

[Cell Death & Disease] Researchers identified that the highly expressed POU Class Homeobox 2 (POU2F2) significantly correlated with poor prognosis of glioblastoma patients. POU2F2 promoted cell proliferation and regulated glycolytic reprogramming.

[Science Translational Medicine] In immunodeficient mice bearing intracerebral patient-derived xenografts with heterogeneous expression of EGFRvIII, a single intravenous infusion of EGFRvIII synNotch-CAR T cells demonstrated higher antitumor efficacy and T cell durability.

[Cancer Research] In patient-derived glioblastoma neurospheres, EGF induced TAZ through EGFR-ERK and EGFR-STAT3 signaling, and the constitutively active EGFRvIII mutation caused EGF-independent hyperactivation of TAZ.

[Cell Reports] Researchers explored the therapeutic potential of targeting mitochondrial translation and report the results of high-content screening with putative blockers of mitochondrial ribosomes.